OBJECTIVES: To investigate whether medication reviews increase treatment with fracture-preventing drugs and decrease treatment with fall-risk-increasing drugs. DESIGN: Randomized controlled trial (1:1). SETTING: Departments of orthopedics, geriatrics, and medicine at Sahlgrenska University Hospital, Gothenburg, Sweden. PARTICIPANTS: One hundred ninety-nine consecutive individuals with hip fracture aged 65 and older. INTERVENTION: Medication reviews, based on assessments of risks of falls and fractures, regarding fracture-preventing and fall-risk-increasing drugs, performed by a physician, conveyed orally and in written form to hospital physicians during the hospital stay, and to general practitioners after discharge. MEASUREMENTS: Primary outcomes were changes in treatment with fracture-preventing and fall-risk-increasing drugs 12 months after discharge. Secondary outcomes were falls, fractures, deaths, and physicians' attitudes toward the intervention. RESULTS: At admission, 26% of intervention and 29% of control participants were taking fracture-preventing drugs, and 12% and 11%, respectively, were taking bone-active drugs, predominantly bisphosphonates. After 12 months, 77% of intervention and 58% of control participants were taking fracture-preventing drugs (P = .01), and 29% and 15%, respectively, were taking bone-active drugs (P = .04). Mean number of fall-risk-increasing drugs per participants was 3.1 (intervention) and 3.1 (control) at admission and 2.9 (intervention) and 3.1 (control) at 12 months (P = .62). No significant differences in hard endpoints were found. The responding physicians (n = 65) appreciated the intervention; on a scale from 1 (very bad) to 6 (very good), the median rating was 5 (interquartile range (IQR) 4-6) for the oral part and 5 (IQR 4-5.5) for the text part. CONCLUSION: Medication reviews performed and conveyed by a physician increased treatment with fracture-preventing drugs but did not significantly decrease treatment with fall-risk-increasing drugs in older adults with hip fracture. Prescribing physicians appreciated this intervention.
RCT Entities:
OBJECTIVES: To investigate whether medication reviews increase treatment with fracture-preventing drugs and decrease treatment with fall-risk-increasing drugs. DESIGN: Randomized controlled trial (1:1). SETTING: Departments of orthopedics, geriatrics, and medicine at Sahlgrenska University Hospital, Gothenburg, Sweden. PARTICIPANTS: One hundred ninety-nine consecutive individuals with hip fracture aged 65 and older. INTERVENTION: Medication reviews, based on assessments of risks of falls and fractures, regarding fracture-preventing and fall-risk-increasing drugs, performed by a physician, conveyed orally and in written form to hospital physicians during the hospital stay, and to general practitioners after discharge. MEASUREMENTS: Primary outcomes were changes in treatment with fracture-preventing and fall-risk-increasing drugs 12 months after discharge. Secondary outcomes were falls, fractures, deaths, and physicians' attitudes toward the intervention. RESULTS: At admission, 26% of intervention and 29% of control participants were taking fracture-preventing drugs, and 12% and 11%, respectively, were taking bone-active drugs, predominantly bisphosphonates. After 12 months, 77% of intervention and 58% of control participants were taking fracture-preventing drugs (P = .01), and 29% and 15%, respectively, were taking bone-active drugs (P = .04). Mean number of fall-risk-increasing drugs per participants was 3.1 (intervention) and 3.1 (control) at admission and 2.9 (intervention) and 3.1 (control) at 12 months (P = .62). No significant differences in hard endpoints were found. The responding physicians (n = 65) appreciated the intervention; on a scale from 1 (very bad) to 6 (very good), the median rating was 5 (interquartile range (IQR) 4-6) for the oral part and 5 (IQR 4-5.5) for the text part. CONCLUSION: Medication reviews performed and conveyed by a physician increased treatment with fracture-preventing drugs but did not significantly decrease treatment with fall-risk-increasing drugs in older adults with hip fracture. Prescribing physicians appreciated this intervention.
Authors: Annelies C Ham; Karin M A Swart; Anke W Enneman; Suzanne C van Dijk; Sadaf Oliai Araghi; Janneke P van Wijngaarden; Nikita L van der Zwaluw; Elske M Brouwer-Brolsma; Rosalie A M Dhonukshe-Rutten; Natasja M van Schoor; Tischa J M van der Cammen; Paul Lips; Lisette C P G M de Groot; André G Uitterlinden; Renger F Witkamp; Bruno H Stricker; Nathalie van der Velde Journal: Drugs Aging Date: 2014-12 Impact factor: 3.923
Authors: M Kastner; L Perrier; S E P Munce; C C Adhihetty; A Lau; J Hamid; V Treister; J Chan; Y Lai; S E Straus Journal: Osteoporos Int Date: 2017-10-18 Impact factor: 4.507
Authors: Christiana Zidrou; Angelo V Vasiliadis; Maria Tsatlidou; George Charitoudis; Anastasios Beletsiotis Journal: J Frailty Sarcopenia Falls Date: 2022-06-01
Authors: Ian D Cameron; Suzanne M Dyer; Claire E Panagoda; Geoffrey R Murray; Keith D Hill; Robert G Cumming; Ngaire Kerse Journal: Cochrane Database Syst Rev Date: 2018-09-07
Authors: Björn Belfrage; Anders Koldestam; Christina Sjöberg; Susanna M Wallerstedt Journal: Eur J Clin Pharmacol Date: 2015-01-09 Impact factor: 2.953
Authors: Björn Belfrage; Anders Koldestam; Christina Sjöberg; Susanna M Wallerstedt Journal: Eur J Clin Pharmacol Date: 2014-05-08 Impact factor: 2.953